# The Utility of Ischemia Modified Albumin (IMA) in Sepsis

> **NCT00448968** · — · COMPLETED · sponsor: **Inverness Medical Innovations** · enrollment: 150 (actual)

## Conditions studied

- Sepsis
- Severe Sepsis
- Systemic Inflammatory Response Syndrome
- Sepsis Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00448968
- **Lead sponsor:** Inverness Medical Innovations
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2007-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448968, "The Utility of Ischemia Modified Albumin (IMA) in Sepsis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00448968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*